Company’s 36-month beta value is 0.89.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KALV is 29.83M, and currently, short sellers hold a 19.17% ratio of that floaft. The average trading volume of KALV on September 30, 2024 was 366.34K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KALV) stock’s latest price update
KalVista Pharmaceuticals Inc (NASDAQ: KALV)’s stock price has gone rise by 23.40 in comparison to its previous close of 10.00, however, the company has experienced a 17.64% increase in its stock price over the last five trading days. businesswire.com reported 2024-09-26 that CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark October 4-5, 2024. The following nine abstracts have been accepted for poster presentation on Friday, October 4 between 6:00-7:00pm CET: Impact of Oral Sebetralstat on Anxiety Associated with Hereditary Angioedema Attacks in the Phase 3 KONFIDENT Trial: Marcus Maur.
KALV’s Market Performance
KALV’s stock has risen by 17.64% in the past week, with a monthly drop of -4.27% and a quarterly rise of 4.75%. The volatility ratio for the week is 8.38% while the volatility levels for the last 30 days are 6.90% for KalVista Pharmaceuticals Inc The simple moving average for the past 20 days is 9.84% for KALV’s stock, with a -0.60% simple moving average for the past 200 days.
Analysts’ Opinion of KALV
Many brokerage firms have already submitted their reports for KALV stocks, with H.C. Wainwright repeating the rating for KALV by listing it as a “Buy.” The predicted price for KALV in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on June 15, 2020 of the previous year 2020.
SVB Leerink, on the other hand, stated in their research note that they expect to see KALV reach a price target of $31. The rating they have provided for KALV stocks is “Outperform” according to the report published on July 29th, 2019.
Needham gave a rating of “Buy” to KALV, setting the target price at $35 in the report published on March 20th of the previous year.
KALV Trading at -1.49% from the 50-Day Moving Average
After a stumble in the market that brought KALV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.90% of loss for the given period.
Volatility was left at 6.90%, however, over the last 30 days, the volatility rate increased by 8.38%, as shares sank -5.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.10% lower at present.
During the last 5 trading sessions, KALV rose by +17.64%, which changed the moving average for the period of 200-days by +40.39% in comparison to the 20-day moving average, which settled at $11.20. In addition, KalVista Pharmaceuticals Inc saw 0.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KALV starting from Palleiko Benjamin L, who sale 7,352 shares at the price of $12.19 back on Sep 09 ’24. After this action, Palleiko Benjamin L now owns 250,800 shares of KalVista Pharmaceuticals Inc, valued at $89,622 using the latest closing price.
Audhya Paul K., the CHIEF MEDICAL OFFICER of KalVista Pharmaceuticals Inc, sale 2,135 shares at $12.40 during a trade that took place back on Aug 23 ’24, which means that Audhya Paul K. is holding 83,745 shares at $26,474 based on the most recent closing price.
Stock Fundamentals for KALV
Current profitability levels for the company are sitting at:
- -128.99 for the present operating margin
- 0.3 for the gross margin
The net margin for KalVista Pharmaceuticals Inc stands at -117.55. The total capital return value is set at -0.88. Equity return is now at value -90.84, with -78.65 for asset returns.
Based on KalVista Pharmaceuticals Inc (KALV), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -16.43.
Currently, EBITDA for the company is -148.08 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 420.96. The receivables turnover for the company is 0.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.55.
Conclusion
In a nutshell, KalVista Pharmaceuticals Inc (KALV) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
